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with control group based on nationwide ambulatory claims data
Abstract
As a condition, diabetes mellitus is associated with risk factors and diseases such as obesity. At the same time, cardiovascular 
diseases are a frequent consequence of diabetes. There have yet to be any findings on the Germany-wide prevalence of 
diabetes and diabetes comorbidities based on statutory health insurance data. This study estimates the documented 
prevalence of diabetes in 2019 on the basis of all ambulatory physicians’ claims data of German statutory health insurance. 
In addition, the prevalence of obesity, high blood pressure, coronary heart disease, heart failure, stroke and depression 
is calculated for diabetes and non-diabetes patients, and the prevalence ratio (PR) is determined as a quotient. The 
approach used was a case-control design, which assigns a control person without diabetes to each diabetes patient who 
is similar in terms of age, region and sex. 
In diabetes patients, a PR greater than 1 was observed for all examined diseases across all age groups, thus demonstrating 
a higher prevalence compared to persons without diabetes. The highest PR across all age groups for women (3.8) and 
men (3.7) was found for obesity. In a comparison over time, documented prevalence figures of diabetes in Germany 
stagnate. With the exception of depression, the documented prevalences of comorbidities correspond well with the 
prevalences found in population-wide examination surveys.
 DIABETES MELLITUS · AMBULATORY CLAIMS DATA · COMORBIDITY · DIABETES SURVEILLANCE
1. Introduction
Over recent decades, type 2 diabetes has gained in public 
health relevance both in Germany and worldwide. On the 
basis of various data sources, studies on the development 
of diabetes prevalence show a tenfold increase in Europe 
and Germany since the 1960s [1]. Population-wide results 
for Germany also show an increase in prevalence over the 
last two decades, and at the same time, there is evidence 
of a high potential for diabetes prevention [2, 3]. Advanced 
age and a family history of the disease, as well as behav-
ioural risk factors such as a lack of physical activity, smok-
ing and poor diet resulting in obesity have been shown to 
be the main risk factors of type 2 diabetes [4]. In addition, 
settings-based risk factors for type 2 diabetes are also being 
discussed. In particular, living environments with few 
opportunities for physical activity, an oversupply of energy- 
rich food or living in a neighbourhood where many people 
Journal of Health Monitoring 2021 6(2)
Diabetes mellitus and comorbidities – A cross-sectional study with control group based on nationwide ambulatory claims dataJournal of Health Monitoring
20
FOCUS
have formally low levels of education have been studied as 
settings-based risk factors [5, 6]. In contrast to type 2 dia-
betes, the other types of diabetes, type 1 and type 3 diabe-
tes, are relatively rare and have other causes.
Long-term elevated blood glucose levels in people with 
diabetes damage the small blood vessels (microangiopa-
thy) and nerves (diabetic polyneuropathy) and can typically 
lead to secondary diseases of the kidneys, eyes or feet [7]. 
In addition, diabetes is an independent risk factor, specif-
ically for cardiovascular diseases such as coronary heart 
disease (CHD) and stroke [8]. 
For Germany, survey data from the Robert Koch Insti-
tute (RKI) for persons aged 50 and older show that the age- 
and sex-adjusted odds of having high blood pressure or a 
cardiovascular disease is 3.60 and 2.35 times higher respec-
tively in persons with diabetes compared to persons with-
out diabetes [9]. In addition, diabetes patients are also 
more likely to suffer mental disorders and, in particular, 
depressive disorders [10]. Irrespective of whether a disease 
such as CHD is to be regarded as a secondary disease of 
diabetes or, like depression, as a common concomitant 
disease, the simultaneous presence of at least one other 
additional disease is referred to as comorbidity. 
Increasingly, statutory health insurance (SHI) claims 
data are being used to assess the frequency of common 
diseases such as diabetes [11–17]. There are also occasional 
analyses of claims data on the frequency of risk factors or 
comorbidities in persons with diabetes compared with per-
sons without diabetes in insurants of single SHI funds. As 
these analyses are based on data from a single health insur-
ance fund [18, 19], their results are not, however, readily 
transferable to the totality of all persons insured by SHI [20]. 
In diabetes surveillance at the RKI, in addition to diabe-
tes prevalence, relevant risk factors as well as secondary 
and concomitant diseases of diabetes are presented and 
recurrently reported [21]. Data from the population repre-
sentative RKI surveys and claims data are used to populate 
indicators [22]. This study aims to examine the prevalence 
of diabetes by age and sex and the frequency of secondary 
and concomitant diseases based on 2019 Germany-wide 
SHI claims data. The selection of diseases is based on an 
expert-consented list that was developed within the frame-
work of diabetes surveillance. The data basis of the analysis 
is the full sample of ambulatory claims data for the year 
2019 [23]. A cross-sectional study was conducted with a con-
trol group in order to compare prevalence values between 
persons with and without diabetes. In addition to age 
group-specific observations, the focus is on comparing the 
sex-related outcomes of diabetes comorbidity burdens. The 
study results are compared with those of the German Health 
Interview and Examination Survey for Adults (DEGS1) [24], 
which was conducted between 2008 and 2011 as an inter-
view and examination survey by the RKI. 
2. Methodology
2.1 Study data
The analysis was based on the pseudonymised Germany- 
wide ambulatory claims data from all health insurance 
funds in accordance with article 295 of the German Social 
Code (SGB) V for 2019 for all patients with SHI, provided 
they had at least one encounter in ambulatory care in the 
year of study. In total, the 2019 data contain information 
on the ambulatory SHI-accredited physician medical care 
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older. The KM 6 statistics provide the absolute numbers 
of insured persons in the lower age segment exclusively 
for the age groups 0 to 14 years and 15 to 19 years. Since 
the absolute number of insured persons aged 18 and 19 
cannot be taken directly from the KM 6 statistics, this fig-
ure was estimated as a basis for determining the size of 
the insured population 18 years and older in 2019. This 
was done under the assumption that the distribution of 
the number of insured persons by age within the 15 to 19 
age group corresponded to that of the 2019 German pop-
ulation figures for this age group. 
2.3 Sample design and study implementation 
To compare the prevalence of cardiovascular diseases, high 
blood pressure, depression and obesity in people with and 
without diabetes in 2019, the study applied a case-control 
design. The design randomly assigned each insured per-
son with diabetes (case) to an insured person as a control 
who had encounters in ambulatory care in at least two 
quarters in 2019 and did not have a documented diabetes 
diagnosis in 2019 or in any previous years. Matching was 
done by age group (5-year age groups), sex and place of 
residence (17 regions representing the different Associa-
tions of SHI-accredited physicians in Germany in order to 
control for the occurrence of these known influencing fac-
tors between the study groups. 
In addition to prevalence estimates of comorbidities in 
both groups, relative differences between groups were 
assessed by the prevalence ratios (PR) which were calcu-
lated as the ratio between the prevalence in the group with 
diabetes and the prevalence in the group without diabetes. 
provided to 56,648,639 patients of adult age. In addition 
to sociodemographic data, e.g. on a patient’s age, sex and 
district of residence, these data also include information 
on the billed ambulatory medical services and diagnoses, 
type of physician, e.g. specialists, or the regional Associa-
tion of Statutory Health Insurance Physicians at which the 
practice is licensed by the SHI. The data are kept at the 
Central Research Institute of Ambulatory Health Care in 
Germany (Zi). To avoid the re-identification of individuals, 
all information was transmitted in aggregated form and 
with a minimum of 30 persons per group set.
2.2 Definition of diabetes and its comorbidities 
The definition of diabetes was based on the code provided 
by the 10th revision of the International Statistical Classi-
fication of Diseases and Related Health Problems (ICD-10) 
used in billing claims data. Insured persons who were diag-
nosed with diabetes mellitus (ICD-10: E10–E14) document-
ed as confirmed in at least two quarters of 2019 (M2Q cri-
terion) were counted as having diabetes in accordance with 
existing definitions [15] and recommendations [25, 26]. The 
selection of diagnoses for the definition of comorbidities 
(Info box) was made according to existing case definitions 
used for the analyses of claims data [11–14] and the M2Q 
criterion was applied throughout.
The documented prevalence of diabetes in 2019 was 
calculated as the number of persons with diabetes as a 
percentage of the total population of SHI-insured persons 
as of 1 July 2019 according to the official statutory health 
insurance member statistics (KM 6 statistics) [27] across 
the age groups 18 to 29, 30 to 59, 60 to 79 and 80 and 
Info box 
Diabetes comorbidities:  
Case definition and description
Obesity
ICD-10 codes: E66.–
▶  Obesity due to excessive calorie intake,  
obesity due to medication and other or 
unspecified forms of obesity
High blood pressure
ICD-10 codes: I10.–, I11.–, I12.–, I13.–, I15.–
▶  Essential hypertension, secondary  
hypertension and diseases of the heart  
or kidney caused by hypertension
Coronary heart disease (CHD)
ICD-10 codes:  I20.–, I21.–, I22.–, I23.–, I24.–, 
I25.–
▶  Angina pectoris, heart attack and chronic 
ischaemic heart disease
Heart failure
ICD-10 codes: I50.–, I11.–, I13.0, I13.2
▶  Heart failure, also as a result of high  
blood pressure
Stroke
ICD-10 codes: I63.–, I64.–, I69.3.–, I69.4.–
▶  Cerebral infarction, stroke and their  
consequences
Depression
ICD-10 codes: F32.–, F33.–, F34.1.–
▶  Depressive disorders and long-lasting 
depressive mood
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years, controls: 68.93 years) and only slight differences in 
the mean spread (standard deviation; cases: 13.71, controls: 
13.84). The utilisation of ambulatory services and the num-
ber of treatment cases was considerably higher in diabetics 
than in controls (Table 1). 
3.2 Prevalence of documented diabetes
Figure 1 shows the prevalence of diabetes according to 
claims data for the year 2019 across the four age groups 
as well as the overall estimate for persons aged 18 and 
older (shown separately for women and men). Overall, 
the prevalence of diabetes increases considerably with 
age. Whereas the documented diabetes prevalence in 
women is 4.4% in the 30 to 59 age group, this rises to 
20.2% in the 60 to 79 age group and is 31.9% in the age 
group 80 years and older. In men, the prevalence is 6.2%, 
27.1% and 36.2% for the three age groups mentioned. 
Only in the 18 to 29 age group is the prevalence higher 
for women (0.76%) than men (0.64%). Across all age 
groups, prevalence for women is lower (11.0%) compared 
to men (12.3%).
The prevalence in persons with diabetes and persons with-
out diabetes as well as the calculated PR value are pre-
sented for each disease according to age group (18- 
to 29-year-olds, 30- to 59-year-olds, 60- to 79-year-olds, and 
80-year-olds and older) for the total estimator and sepa-
rately for women and men. 
Data extraction and analysis were carried out using 
SAS 9.4 software and results visualised with the freely 
avail able R version 3.6.1 program using the tidyverse pro-
gram package [29]. 
3. Results 
3.1 Sociodemographic factors and health care use 
Table 1 provides an overview of sociodemographic factors 
and SHI-accredited physician appointments and compares 
the two groups studied. In total, more than seven million 
people with diabetes, as per the definition provided, were 
identified and compared with an equal number of controls. 
Based on the study design, the proportion of women was 
the same in both groups (49.79%). The age in the two 
groups showed an almost identical mean (cases: 68.99 
Table 1 
Features of the two groups analysed 
(case and control group) 
Source: Germany-wide claims data from 
SHI-accredited physicians for adults covered by 
statutory health insurance, own calculations
Case group with diabetes Control group without diabetes
Number of persons 7,068,249 7,068,249
Proportion of women in % 49.79 49.79
Average age (SD) 68.99 (13.71) 68.93 (13.84) 
Treatment cases1 per person and year (mean value) 14.21 10.98
Services2 per person and year (mean value) 126.75 83.57
Value of services in euros (mean value) 1,147.98 815.50
SD = standard deviation
1  Treatment cases are defined in § 21 Para. 1 of the Bundesmantelvertrag-Ärzte (BMV-Ä) as treatment of the same insured person by the same medical practice in 
a calendar quarter at the expense of the same health insurance fund [28].
2  This indicator records the number of invoiced fee schedule items for individual medical services, such as home visits or specific diagnostic and therapeutic  
services, but also invoiced fee schedule items that represent flat rates for service complexes, such as primary care or specialist care.
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PR for obesity decreases with age: it is still 5.6 in the 30 to 
59 age group, falling to 3.6 in the 60 to 79 age group and 
2.8 in the age group 80 years and older. The decrease in 
PR across age groups is due to the prevalence of obesity 
in women, with diabetes decreasing earlier and more with 
age. While the highest prevalence of obesity (46.3%) among 
women with diabetes is found in the 30 to 59 age group, 
the highest prevalence among women without diabetes 
(10.1%) is found in the 60 to 79 age group. In this age 
group, the prevalence for women with diabetes is 36.6% 
and thus already considerably lower compared to younger 
age groups.
Across all age groups, the prevalence of hypertension 
in women with diabetes is 80.7%, 1.4 times higher than in 
women without diabetes (56.0%). Women with diabetes 
are eight times more likely to have documented high blood 
pressure in the youngest age group of 18- to 29-year-olds, 
with a prevalence of 12.6%, than women without diabetes 
(1.6%). With increasing age, the differences in prevalence 
between the study groups decrease, a fact due to a higher 
relative increase in prevalence in the group of women with-
out diabetes. In the group of women aged 80 years and 
older, the prevalence in the group with diabetes is 1.2 times 
higher at 90.0% compared to the group without diabetes 
(76.7%). A similar picture can also be seen for heart failure, 
stroke and CHD. All these cardiovascular diseases show 
large relative differences in prevalence between the study 
groups, especially in the young age groups (30- to 59-year- 
olds), which decrease with rising age. Across all age groups, 
women with diabetes show a 1.7- to 1.9-fold higher preva-
lence for heart failure (20.2%), CHD (20.7%) and stroke 
(6.8%) compared to women without diabetes.
3.3 Prevalence and prevalence ratios of diabetes  
comorbidities
Figure 2 and Figure 3 show prevalence estimates of comor-
bidities in women and men with diabetes and without dia-
betes. A PR greater than 1 indicates that the prevalence of 
the respective condition is higher in the group with diabe-
tes than in the group without diabetes. No values are shown 
in cells where the number of persons included in either 
study group is less than 30. This applies to the 18 to 29 age 
group for heart failure, CHD and stroke in women and men. 
3.4 Results by age group for women 
Across all age groups, obesity prevalence (34.2%) is 3.8 
times higher in the group of women with diabetes com-
pared to those without documented diabetes (9.1%). 
Hence, of all the diseases analysed here, obesity has the 
strongest association with diabetes in women. In the age 
group of 18- to 29-year-old women with diabetes, the preva-
lence of obesity is 7.6 times higher (30.7%) compared to 
those without diabetes (4.0%), the highest relative differ-
ence in prevalence between the two groups studied. The 
Figure 1 
Documented prevalence of diabetes 
by age group and sex in 2019 
(n = 3,518,968 women, n = 3,549,281 men) 
Source: Germany-wide claims data from 
SHI-accredited physicians for adults covered by 
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of 2.1, compared to women without diabetes (6.9%). 
Depression prevalence (29.5%) is highest among women 
with diabetes in the 30 to 59 age group, whereas the high-
est prevalence in women without diabetes (22.9%) is found 
in the age group 80 years and older.
Across all age groups, the prevalence of depression is 
around 1.4 times higher in women with diabetes than in 
women without diabetes (26.9% vs. 19.8%). Here, too, 
women with diabetes in the youngest age group of 18- to 
29-year-olds show the highest relative difference, with a PR 
Figure 2 
Documented prevalence and prevalence ratio 
for selected diseases in women with 
and without diabetes by age group 
(n = 3,518,968 women with diabetes, 
n = 3,518,968 women without diabetes)
Source: Germany-wide claims data from 
SHI-accredited physicians for adults covered by 
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strongly associated with diabetes in men. Figures across 
age groups for men are also similar to those found for 
women. Prevalence for men with diabetes (17.1%) is already 
6.1 times higher in the younger age group of 18- to 29-year-
olds compared to men without diabetes (2.8%). The 
3.5 Results by age group for men
Obesity prevalence among men with documented diabetes 
(30.2%) is 3.7 times higher compared to men without dia-
betes (8.1%). As in women, obesity is therefore most 
Figure 3 
Documented prevalence and prevalence ratio 
for selected diseases in men with and without 
diabetes by age group (n = 3,548,968 men with 
diabetes, n = 3,548,968 men without diabetes) 
Source: Germany-wide claims data from 
SHI-accredited physicians for adults covered by 
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In contrast to the figures for CHD, the prevalence of 
depression is lower in men in both groups compared to 
women. For men with diabetes, the prevalence of depres-
sion across all age groups is 15.9%, 1.4 times higher than 
for men without diabetes (11.4%). The highest prevalence 
of depression (17.6%) is found in men with diabetes in the 
30 to 59 age group and in men without diabetes in the 30 
to 59 age group (11.6%) but there are only minor differ-
ences to the higher age groups. 
4. Discussion
Based on the full sample of ambulatory claims data of 
SHI-accredited physicians, the current study assessed the 
prevalence of important comorbidities of diabetes com-
pared to persons without diabetes. In line with a study 
based on data from the AOK Baden-Württemberg [18], 
which specifically analysed the case of type 2 diabetes and 
was based on a comparable methodology, this study also 
shows a higher prevalence for persons with diabetes for 
each disease. In contrast to the aforementioned study [18], 
the results in this study are based on data from all SHI- 
accredited physicians in Germany and therefore allow con-
clusions to be drawn that apply to all diabetes patients cov-
ered by SHI. The results highlight both the importance of 
diabetes as a frequent consequence of behavioural risk 
factors and the strong links of diabetes with other dis eases, 
especially cardiovascular disease. The study design pro-
vides insights into the specific age- and sex-related factors 
of frequent concomitant diseases of diabetes. Compared 
to people without diabetes, women and men with diabetes 
are considerably more likely to be severe overweight and 
highest prevalence of obesity in men with diabetes (36.5%) 
is found in the 30 to 59 age group; for men without diabe-
tes, it is found in the 60 to 79 age group (8.9%). With age, 
the differences in prevalence become relatively smaller, 
which – as in women – coincides with a faster and relative-
ly greater decrease in the prevalence of obesity in the group 
with diabetes compared to the group without diabetes. 
Across all age groups, the prevalence of high blood pres-
sure in men with diabetes is 79.0% and is 1.4 times higher 
than in men without diabetes (55.1%). With regard to high 
blood pressure, the picture is similar to that of women 
across all age groups. For men, too, the relative difference 
is highest in the 18 to 29 age group, with a 4.8 times higher 
prevalence (14.3%) in the group with diabetes compared 
to the group without diabetes (3.0%). With age, prevalence 
in the groups gradually equalises and the PR factor 
decreases to 1.2 in the age group 80 years and older. The 
highest prevalence of high blood pressure is reached in the 
age group 80 years and older (persons with diabetes: 88%, 
persons without diabetes: 72.6%).
The prevalence of heart failure and stroke are identical 
or slightly higher across all age groups with values between 
20.2% and 8.0% for men with diabetes and 10.8% and 
4.9% for men without diabetes compared to the figures for 
women. Progressively, for all age groups, the prevalence 
for men with diabetes is higher compared to men without 
diabetes. The highest prevalence in both study groups is 
again found in the age group 80 years and older. 
In spite of a similar PR, men are significantly more likely 
to be affected by CHD. CHD prevalence across all age 
groups is 33.0% in men with diabetes and 1.8 times higher 
compared to men without diabetes (17.6%). 
Women and men with 
diabetes show a higher  
prevalence for all studied 
comorbidities and across  
all age groups compared  
to women and men  
without diabetes.
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If we limit the analysis in this study to the age range 
covered by the population representative DEGS1 survey 
(2008–2011, 18- to 79-year-olds), the documented preva-
lence for women was 8.5% and 10.5% for men. According 
to DEGS1, the prevalence of known diabetes in relation to 
persons covered by SHI is 7.8% for women and 7.2% for 
men, with gestational diabetes accounting for 1.2% of the 
population-wide prevalence in women [3]. Assuming there 
is strong correlation between the prevalence of known dia-
betes in claims data and the diagnosis prevalence found 
by DEGS1 collected by physician interviews, the compari-
son of prevalence figures by sex of DEGS1 with the results 
of this study indicate a considerable increase in docu-
mented diabetes between the years when data for DEGS1 
were collected and 2019. With regard to the documented 
prevalence, an earlier analysis of the nationwide ambula-
tory claims data of people covered by SHI [30] already 
showed an increase across all age groups from 9.00% to 
9.96% between 2010 and 2015, which means a relative 
increase of around 11% or, in absolute terms, of around 
700,000. Much of this increase (around 8%, or roughly 
500,000) occurred between 2010 and 2013. A comparison 
of the years 2015 and 2019 shows that the case numbers 
for documented diabetes mentioned above stagnated. The 
higher documented prevalence in 2019 compared to DEGS1 
is therefore presumably partly owed to a strong increase 
in prevalence in the years up to 2015. A further decrease in 
the proportion of undiagnosed diabetes since 2010 could 
very well account for a part of this difference, as its decrease 
would simultaneously mean an increase in documented 
cases of diabetes. In DEGS1, the proportion of undiagnosed 
diabetes was still 1.2% for women and 2.9% for men, and 
have elevated blood pressure, even at a younger age. As a 
result, the burden of disease due to cardiovascular diseases, 
but also depression, is greatly increased across all age 
groups, but especially in people under 60 years of age. 
4.1  Prevalence of documented diabetes 
To estimate the development of the documented prevalence, 
the diabetes prevalence figures derived from Germany- 
wide 2019 claims data were compared to the 2013 diabetes 
surveillance figures. The documented prevalence in the 
earlier study was calculated using the data set provided 
according to Germany’s Data Transparency Ordinance 
(DaTraV data), which in addition to the ambulatory claims 
data used here includes inpatient claims data of all patients 
covered by SHI [7]. Across all adult age groups the preva-
lence found in DaTraV data in 2013 was 11.2% for women 
and 12.6% for men [29]. In comparison with the rates this 
study found for 2019 (11.0% for women and 12.3% for men), 
the prevalence is slightly lower below the 2013 figures. The 
small difference of prevalence estimates derived from 
DaTraV data and the present analysis indicate that the doc-
umented prevalence has stabilised at a high level, an inter-
pretation also corroborated by another analyses of SHI 
claims data [19]. A further indication that the documented 
prevalence has stagnated at a high level is found when 
comparing the 2015 figures for people with diabetes, which 
were based on the same data source and case definition 
[30]. While the 2015 study identified 6,955,865 people with 
diabetes, this study counted 7,068,249 persons with dia-
betes in 2019, in spite of excluding persons younger than 
18, who are, however, rarely affected by diabetes. 
In comparison over time,  
the documented prevalence 
of diabetes in 2019 stagnates 
at a high level.
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lence for persons with diabetes shown in this paper from 
the 60 to 79 age group cannot be confirmed with the 
DEGS1 data published, as here the total population is con-
sidered. However, more severe forms of obesity, which are 
also more strongly associated with diabetes [35], already 
begin to decrease in the 60 to 69 age group in DEGS1 [34]. 
As there are published study results showing that account-
ing data predominantly document severe forms of obesity 
[36] and that persons suffering obesity and diabetes have 
an increased mortality [37], the results presented here indi-
cating a high prevalence in young age groups combined 
with a decline occurring early in life are epidemiologically 
highly plausible. 
DEGS1 shows a prevalence of drug-treated or measured 
high blood pressure of 76.4% for 45- to 79-year-old type 2 
diabetes patients [38]. Notably, both the values for individ-
uals in the 65- to 79-year-old age group in DEGS1 (85.5% 
for women and 80.3% for men) and for the 60- to 79-year-
old age group in this study (women 84.5%, men 83.8%) 
are similarly high. Thus, the documented prevalence of 
high blood pressure in persons with documented diabetes 
in this study is comparable to that of DEGS1 – a result that 
is supported by the high validity of documented billing 
diagnoses for high blood pressure [36, 39].
Unlike high blood pressure prevalence, the prevalence 
of obesity in people with diabetes did not decline between 
the RKI surveys [33, 40]. Since obesity already becomes 
apparent at a young age and its development and course 
can be strongly influenced by behavioural and settings- 
based factors, there is considerable potential for preven-
tion here with regard to the burden of disease and prema-
ture mortality.
was thus already considerably lower than in the previous 
German National Health Interview and Examination Sur-
vey 1998 (GNHIES98) [1]. Clarification of the time trend 
will be provided by future population-wide examination 
surveys conducted by the RKI. In principle, the guidelines 
for diabetes diagnostics and in particular the threshold val-
ues used for measured parameters, such as long-term 
blood glucose levels (HbA1c value), incorporate new find-
ings, which could also have an influence on the develop-
ment of prevalence over time [31].
4.2 Obesity and high blood pressure prevalence  
in diabetes patients
The strongest association with diabetes, both in women 
and men, is seen for obesity and high blood pressure. This 
result is consistent with the biological mechanisms 
described, according to which people with obesity are more 
likely to develop diabetes, whereby obesity and diabetes 
are likewise considerable risk factors for developing high 
blood pressure [32]. As shown in DEGS1, the population 
representative prevalence of obesity (Body Mass Index 
≥ 30 kg/m2) for people with type 2 diabetes (aged 45 to 79) 
was 54.4% [33] and thus higher than the prevalence deter-
mined in this study: in the 30 to 59 age group, the preva-
lence of obesity was 46.1% for women and 36.6% for men; 
in the 60 to 79 age group, the figures stood at 36.5% for 
women and 31.1% for men.
For the total population of 18- to 79-year-olds, DEGS1 
shows an increased prevalence of obesity in women, espe-
cially of more severe forms, which is in line with the results 
from this study [34]. The pronounced decrease in preva-
The highest relative  
difference in prevalence 
between people with and 
without diabetes in women 
and men is found for obesity.
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of diabetes surveillance shows that 19.1% of women and 
12.3% of men with diabetes show depression symptoms 
in adulthood [42]. Between the groups with and without 
diabetes, the analysis, moreover, shows that the age- 
adjusted likelihood for a person to develop depression 
symptoms is twice as high for people with diabetes com-
pared to people without the disease [42]. International find-
ings corroborate this [10]. In accordance with these results, 
this analysis shows a higher prevalence of depression for 
the group with diabetes and for women. For women aged 
18 years and older with diabetes, this analysis shows a doc-
umented prevalence of 26.9% and 15.9% for men. The con-
siderably higher figures found in the documented diagno-
ses relative to those found in survey data are known and 
have been discussed in detail elsewhere [14]. The main 
reason for this discrepancy is likely to be the specific defi-
nition of depression in clinical interviews, which determines 
the condition at a level of detail not possible using solely 
claims data [14, 43]. 
4.5 Strengths and limitations of the study 
This study is based on all the ambulatory diagnoses of 
patients covered by SHI using claims data from SHI- 
accredited physicians. This avoids a distortion of the cal-
culated Germany-wide documented prevalence that could 
result from different compositions regarding age structure 
and other risk factors among members of individual health 
insurance funds or SHI-accredited physician associations. 
Compared to survey data, the inclusion of all age groups 
is a particular strength of claims data and thus of the study 
presented here. In particular, the old and very old were not 
4.3 Cardiovascular disease prevalence in diabetes 
patients
For persons with type 2 diabetes 45- to 79-years-old, DEGS1 
estimates the prevalence of at least one cardiovascular dis-
ease to be at 37.1% [33]. Comparing this value with avail-
able study data is difficult due to the more detailed pre-
sentation of analysis for individual diseases from the larger 
group of cardiovascular diseases chosen here. However, if 
one assumes, for the purpose of comparison, that heart 
failure develops on the basis of CHD and that stroke, which 
occurs in older age groups, also overlaps with CHD, an 
estimate based on CHD alone is possible. According to 
this assumption, the prevalence found by DEGS1 is higher 
than the prevalence documented in the claims data in the 
30 to 59 and 60 to 79 age groups in women (6.2%, 19.1%) 
and men (13.7%, 33.7%) as part of this analysis. This con-
firms the result of a recent study [11], which, based on the 
same data and case definition, shows a moderately lower 
prevalence for the documented prevalence of CHD com-
pared to DEGS1. The strong association between the doc-
umented and population representative prevalence for 
CHD is also supported by the fact that the sex-specific char-
acteristics of a considerably higher population represen-
tative raw disease prevalence for women are also reflected 
by claims data prevalences [11, 41]. 
4.4 Depression prevalence in diabetes patients
Compared to the diseases discussed so far, depression and 
diabetes differ in their biological mechanisms, as well as 
their risk and influencing factors. Nevertheless, an analysis 
With the exception of  
depression, the documented 
prevalence of the examined 
diseases shows good  
agreement with population 
representative prevalence.
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considerably more often in claims data than in clinical diag-
nosis data [14, 43, 45]. This study does not operationalise 
patients’ social situation as the corresponding indicators 
often used, such as income, occupational status or educa-
tional status, are not present in the data. For this reason, 
the prevalence ratios presented here are not adjusted for 
differences in educational attainment between people with 
and without diabetes. In particular, as results show diabe-
tes prevalence reflects social inequalities [46], the preva-
lence ratios presented here are skewed to a degree that 
depends on the unknown distribution of social situation 
indicators between persons with and without diabetes. 
In general, it must be assumed that risk factors and 
concomitant diseases are also coded more frequently in 
persons with a documented chronic disease such as dia-
betes [36, 39, 47]. To mitigate this effect, in this analysis 
the persons with diabetes were compared to a control 
group of persons with an appointment at a SHI-accredited 
physician in at least two quarters. 
In contrast to the data from SHI providers, the data in 
this study do not include inpatient diagnoses, drug pre-
scriptions or, in particular, persons without ambulatory 
encounter. Due to the lack of people with SHI without 
ambulatory encounter, prevalence cannot be calculated on 
the basis of the data alone, as the total population of peo-
ple with SHI cannot be determined directly. This study 
addressed this limitation by using the official member sta-
tistics of SHI providers – called the KM 6 statistics – to 
estimate the total SHI population. For the other limitations, 
i.e. absence of inpatient diagnoses and drug prescriptions, 
the comparison of the study’s documented prevalence with 
the results of the literature considered in this article shows 
included in the previous nationwide survey data, where the 
age range was limited to a maximum of 79. In addition, 
claims data are routinely collected regardless of a patient’s 
willingness to participate. Consequently, the data covers 
large swathes of the population. Ultimately, the scope of 
information made available through claims data also allows 
for deeply stratified analyses by age, region and sex. Over-
all, the fast availability of SHI-accredited physician claims 
data within less than one year is advantageous. These data 
thus make it possible to show changes in morbidity quickly. 
A fundamental disadvantage of SHI claims data is that 
patients with private health insurance are not included and 
that services provided outside the statutory claims system 
are not documented. Although the majority of the German 
population is covered by SHI, it is estimated that informa-
tion about the illness history of 12.2% of the population is 
not recorded in these data, and they are therefore not rep-
resentative of the population [44].
Especially in comparison with the population represen-
tative DEGS1 study, the prevalences calculated in this study 
for 2019 correspond well with the epidemiological results 
by sex and age group. In particular regarding diseases 
where billing diagnoses and clinical diagnoses are known 
to show a strong correlation, such as diabetes, high blood 
pressure and cardiovascular diseases, the study results are 
robust. However, compared to the prevalences found in 
examination surveys such as DEGS1, risk factors such as 
being overweight and obesity appear to be under-coded or 
not recorded. The documented prevalence of depression 
calculated in our study, which is considerably higher com-
pared to the prevalence found by DEGS1, is difficult to clas-
sify. Studies show that depression, in particular, is coded 
Claims data of all ambulatory 
statutory health insurance 
physicians are well suited  
for the regular analysis of 
diabetes comorbidity in 
diabetes surveillance.
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that for common chronic diseases, the ambulatory SHI- 
accredited physician care of all persons covered by SHI 
captures the disease situation well.
5. Conclusion
Using current and Germany-wide ambulatory claims data, 
this study underscores that, on the whole, persons with 
diabetes, but especially those at younger adult age, have a 
considerably increased disease burden due to severe over-
weight, elevated blood pressure and cardiovascular disease. 
The claims data of all ambulatory services provided by 
SHI-accredited physicians are suited to continuously assess 
diseases of high public health relevance. In particular, dia-
betes surveillance at the RKI could benefit from a regular 
assessment of diabetes prevalence and diabetes comorbid-
ities as documented in claims data. If repeated, the chosen 
study approach would also enable estimates of changes in 
the comorbidity burden in a comparison of persons with 
and without diabetes.
Lastly, the ongoing COVID-19 pandemic underlines 
the importance of systematically monitoring and assess-
ing the development of diabetes and diabetes comorbid-
ities. Analyses show that persons with diabetes, obesity, 
cardiovascular as well as other chronic diseases also suf-
fer greater complications when they develop COVID-19, 
such as hospital admission, ventilation or death, regard-
less of age and are more likely to die from the disease 
[48]. Similar effects have also been documented for other 
viral infections such as seasonal influenza [49]. An 
improved health situation and care of the population 
would likely also lead to a decrease in the number of 
severe courses of the disease [50]. 
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